ADVFN - Advanced Financial Network.
HOME» NYSE » A » ABT Stock Price » ABT Stock News

Abbott Labs Share News

 Abbott Laboratories Stock Price
ABT Stock Price
 Abbott Laboratories Stock Chart
ABT Stock Chart
 Abbott Laboratories Stock News
ABT Stock News
 Abbott Laboratories Company Information
ABT Company Information
 Abbott Laboratories Stock Trades
ABT Stock Trades

Abbott Buys AP214 Hormone From Action Pharma For $110 Million

DOW JONES NEWSWIRES Abbott Laboratories (ABT) took another step to enhance its renal-care pipeline by agreeing to acquire AP214, a hormone analogue that may prevent acute kidney injury during cardiac surgery, from Action Pharma A/S for $110 million in cash. The health-care company has been on a buying spree in recent years in order to reduce its dependence on the anti-inflammatory Humira as the drug's U.S. patent expires in late 2016. Abbott also is in the midst of separating into two publicly traded companies: a medical-products business and a pharmaceutical company to be named AbbVie. Abbott will acquire all global rights to develop and market AP214, and will be responsible for funding all future development and commercialization activities. No later milestone payments or royalties will be paid to the Danish biotech company Action Pharma. Abbott currently has two investigational treatments in development for chronic kidney disease: Bardoxolone, which is in Phase 3 development with Reata Pharmaceuticals, and Atrasentan, a compound discovered by Abbott being evaluated in a Phase 2b study. -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

Stock News for Abbott Labs (ABT)
DateTimeHeadline
02/08/201609:11:00Law Offices of Marc S. Henzel Announces Investigation of Companies...
02/04/201612:19:00SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches an...
02/04/201607:00:00Children in Europe Now Have Access to First-Of-Its-Kind Diabetes...
02/02/201615:59:00INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of...
02/02/201613:31:00ALERE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA:...
02/02/201608:39:32Aqua Bio Technology: Minutes from Extraordinary General Meeting...
02/02/201603:02:00Medical-Device Firms Use Deals To Branch Out
02/01/201618:00:00Medical Tech Firms Branch Out
02/01/201617:42:00Medical Technology Firms Branch Out
02/01/201610:14:00Abbott Labs to Acquire Diagnostics-Testing Company Alere--Update
02/01/201609:30:00Abbott Labs to Acquire Alere
02/01/201609:24:00Abbott Labs to Acquire Diagnostics-Testing Company Alere
02/01/201608:00:00Abbott to Acquire Alere, Becoming Leader in Point of Care Testing...
01/28/201613:05:00Abbott Labs Profit Falls, Hurt by Currency -- Update
01/28/201609:30:00Abbott Labs Profit Falls, Hurt by Currency
01/28/201609:22:00Abbott Labs Profit Falls, Hurt by Currency
01/28/201607:40:49Current Report Filing (8-k)
01/28/201607:30:00Abbott Reports Fourth-Quarter 2015 Results
01/19/201600:01:00Specialized nutrition supplement is associated with a 50 percent...
01/18/201608:00:00Specialized nutrition supplement is associated with a 50 percent...

Abbott Laboratories and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad